Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs

An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira):

adalimumab (Humira)  is  accepted  for  restricted  use  in  NHS  Scotland,  in  combination  with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17  years  who  have  an  inadequate  response  to  one  or more  disease-modifying  anti-rheumatic drugs (DMARDs).  Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

It should be  restricted  to use within specialist rheumatology services (including  those working within the network  for paediatric rheumatology).   Adalimumab is one of  three TNF-antagonists  listed  in  the British National Formulary  for Children as drugs  that  suppress  the  rheumatic disease process, and one of two of those drugs licensed for active polyarticular juvenile idiopathic arthritis.

The Scottish Medicines Consortium  has  previously  accepted  this  product  for  restricted  use  for  this indication in adults.

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.

laptop2


 

 

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos